Quantcast

Latest pharmaceutical industry Stories

2014-07-23 16:26:32

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2243630/Intracerebral-Hemorrhage-Global-Clinical-Trials-Review-H2-2014.htmlIntracerebral Hemorrhage Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014" provides data on the Intracerebral Hemorrhage...

2014-07-23 12:32:49

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Hypoxic-Ischemic Encephalopathy Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2243628/Hypoxic-Ischemic-Encephalopathy-Global-Clinical-Trials-Review-H2-2014.htmlHypoxic-Ischemic Encephalopathy Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Hypoxic-Ischemic Encephalopathy Global Clinical Trials Review, H2, 2014" provides data on...

2014-07-23 12:32:31

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Generalized Seizures Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2243626/Generalized-Seizures-Global-Clinical-Trials-Review-H2-2014.htmlGeneralized Seizures Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Generalized Seizures Global Clinical Trials Review, H2, 2014" provides data on the Generalized Seizures clinical trial...

2014-07-23 12:31:16

Study quantifies lost savings from REMS and related restricted access tactics WASHINGTON, July 23, 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies (REMS) and other restricted access programs to delay generic market entry results in $5.4 billion in lost savings annually, according to a new survey and analysis by economic consulting firm Matrix Global Advisors (MGA). Logo - http://photos.prnewswire.com/prnh/20140723/129680 Required by the Food and Drug...

2014-07-23 12:30:34

CLEVELAND, July 23, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a clinical-stage biotechnology company developing a first-in-class regenerative gene therapy for treatment of heart failure announced adding two industry veterans to its leadership team. Dale Sander has joined as Chief Financial Officer. Dr. Francis Plat will serve in an advisory capacity as Chief Strategy Officer. http://photos.prnewswire.com/prnvar/20131028/DC04442LOGO Mr. Sander has more than 20 years of...

2014-07-23 08:31:39

BOSTON, July 23, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on July 31, 2014, to discuss financial results for the second quarter ended June 30, 2014. The call details are as follows: Date: Thursday, July 31, 2014 Time: 8:30 am EDT Dial-in numbers: Toll free: (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or, International: (412)...

2014-07-23 08:31:10

ENGLEWOOD, Colo., July 23 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility: Ampio Pharmaceuticals,373 Inverness ParkwayEnglewood, CO 80112Direct: (720) 437-6500 Michael Macaluso, Ampio's CEO, noted "This advanced, labor efficient, pharmaceutical drug manufacturing facility will be fully operational this summer, right on schedule, to produce the first batches of Ampion(TM)...

2014-07-23 08:30:59

MARIETTA, Ga., July 23, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND") application with the Food and Drug Administration ("FDA"). The IND submission, which was filed yesterday, July 22, 2014, is the Company's initial submission for certain indications...

2014-07-23 08:30:55

LONDON, July 23, 2014 /PRNewswire/ -- Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition and supply disruptions to its Consumer business. However its CEO Sir Andrew Witty points out that the company is very much in transition, citing progress in the development pipeline as reason to be confident about long-term prospects as well as the investments being made to drive long-term growth. CFO...

2014-07-23 08:30:32

District Court Judge Orders Apotex to Immediately Recall the Authorized Generic from its Direct Customers and to Stop Selling and Supplying the Product PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil(®)...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related